Core Insights - BridgeBio Pharma presented positive interim analysis results from the Phase 3 FORTIFY trial of BBP-418 for LGMD2I/R9, indicating broad efficacy across key clinical endpoints and subgroups [1][2] - The company plans to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a potential U.S. launch in late 2026 or early 2027 [1][4] - If approved, BBP-418 could be the first therapy for LGMD2I/R9 and potentially the first approved treatment for any form of limb-girdle muscular dystrophy (LGMD) [1][4] Efficacy Findings - Early separation from placebo was observed in the 100-meter timed test (100MTT), with improvements in ambulation noted as early as three months after starting BBP-418 treatment [1][3] - At 12 months, BBP-418-treated individuals completed the 100MTT approximately 31 seconds faster than those on placebo [3] - The 10-meter walk test (10MWT) showed BBP-418 participants improved by 0.13 m/s, while the placebo group declined by 0.10 m/s [3] Safety Findings - BBP-418 was generally well tolerated, with treatment-emergent adverse events (TEAEs) reported in 93.2% of BBP-418 recipients compared to 100% in the placebo group [3][6] - Serious TEAEs occurred in 5.4% of BBP-418-treated individuals versus 7.9% in the placebo group, with no treatment-related serious TEAEs reported [3][6] - The most common TEAEs in the BBP-418 group included diarrhea (39.2%), procedural pain (20.3%), and falls (18.9%) [4][6] Future Plans - BridgeBio intends to initiate clinical studies of BBP-418 for individuals under 12 years of age and in other LGMD subtypes in the near future [4] - The company is also engaging with regulatory agencies to explore expedited approval pathways for BBP-418 in Europe [4]

Summary of BridgeBio's 2026 Conference Call Company Overview - **Company**: BridgeBio (NasdaqGS:BBIO) - **Event**: 2026 Leerink Partners Global Healthcare Conference - **Date**: March 10, 2026 Key Points TTR Market and Attruby Performance - **Patient Growth**: Accelerated from approximately 60 patients per week at launch to over 150 patients per week, indicating strong market acceptance [3][5] - **Market Dynamics**: The growth is attributed to: - Strong clinical data supporting Attruby as the first near-complete stabilizer for TTR [3] - Increased disease awareness and improved diagnosis through AI initiatives [4] - Broader prescriber base, particularly high-volume heart failure clinics [4][5] - **Market Share**: Achieved over 25% share in treatment-naive patients within a year of launch, with a goal of exceeding 30% [5] - **Pricing Stability**: Net pricing for Attruby remains stable, with gross-to-net ratios in the 30%-40% range [6][7] European Market and BEYONTTRA - **Partnership with Bayer**: Successful collaboration for the launch of BEYONTTRA, with over 50% treatment-naive share in Germany due to a single-payer system [9][10] - **Future Launches**: Upcoming launches planned in Denmark, Spain, Italy, and France, with royalties starting at 30% [11] Combination Therapy and Competitive Landscape - **Tafamidis IP Discussion**: Potential outcomes for tafamidis patent litigation could impact market dynamics, with expectations of generic entry possibly in the 2030s [12] - **Combination Therapy Insights**: Current data shows no significant benefits from combination therapies, with a focus on establishing Attruby as the most potent stabilizer [13][14] Pipeline Developments - **Depleter Program**: BridgeBio is developing an in-house depleter to complement Attruby, targeting the removal of monomers that cause cardiomyopathy [15][16][17] - **Achondroplasia Strategy**: Infigratinib is positioned as a superior oral treatment option, with a focus on market expansion through patient switches from injections [18][22][23] - **Global Launch Plans**: International strategy involves a phased approach, starting with Germany, with regulatory filings expected to lag behind U.S. timelines by 3-4 months [27][28] Financial Outlook and Margin Profile - **Cost Management**: R&D expenses are expected to remain flat, while SG&A expenses will increase due to upcoming launches [39] - **Margin Expectations**: Anticipated gross margins for new products could reach 70%-80%, with a significant increase in total operating spend as new products launch [50] Additional Insights - **Equity Stake in GondolaBio**: BridgeBio holds an equity stake in GondolaBio, an early-stage R&D engine, which may be integrated into future strategies [52] This summary encapsulates the critical insights and strategic directions discussed during the conference call, highlighting BridgeBio's growth trajectory, market strategies, and financial outlook.

Core Insights - Design Therapeutics, Inc. is advancing its GeneTAC® portfolio with three clinical programs, including DT-818 for myotonic dystrophy type-1 (DM1), DT-216P2 for Friedreich ataxia (FA), and DT-168 for Fuchs endothelial corneal dystrophy (FECD) [2][5] Clinical Programs - The company is expected to initiate patient dosing in the Phase 1 trial of DT-818 in DM1 in the first half of 2026, with results anticipated in 2027 [2][6] - Ongoing trials include RESTORE-FA for DT-216P2, with an update on frataxin levels expected in the second half of 2026, and a Phase 2 biomarker trial for DT-168, with data also anticipated in the second half of 2026 [6] Financial Performance - For Q4 2025, research and development expenses were $13.4 million, while general and administrative expenses were $4.7 million, leading to a net loss of $16.0 million [4][10] - For the full year 2025, total operating expenses reached $79.5 million, with a net loss of $69.8 million [10] - As of December 31, 2025, the company reported cash and securities of $219.8 million, which is expected to fund operations into 2029 [6][11] Pipeline Development - The company is also advancing preclinical characterization for several candidate molecules targeting Huntington's disease and exploring multiple genomic medicine discovery efforts [5][7]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [32][33] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, driven primarily by a $359.5 million increase in net product revenue from Attruby [33][34] - Operating costs for Q4 2025 were $293.7 million, compared to $231.9 million in the same period last year, with a notable increase in SG&A expenses [34][35] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, with new patient starts reaching 7,804 [24][32] - The company reported a 35% quarter-over-quarter growth in net product revenue for Attruby, indicating strong commercial momentum [24][25] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in unique patient prescriptions [18][24] - The company noted that the adoption of Attruby is accelerating, particularly in first-line patients, surpassing previous expectations [25][30] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with expectations of cash generation starting in late 2027 and becoming a cash generation engine by 2028 [8][9] - The focus remains on advancing three additional product candidates towards commercialization, with a strong emphasis on maintaining a best-in-class commercial engine for genetic diseases [10][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's fundamentals, despite recent stock volatility, and emphasized the intrinsic value of BridgeBio is increasing [11][12] - The company is actively evaluating options to ensure shareholder value is recognized, with over $1 billion in capital available to support its strategic initiatives [12][36] Other Important Information - The company has successfully completed three late-stage readouts, marking a transformative inflection point for BridgeBio [4][5] - Management highlighted the importance of clinical data in driving market share and emphasized the differentiated profile of Attruby compared to competitors [10][23] Q&A Session Summary Question: What drives Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient needs, leading to high adoption rates [39][41] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the year, focusing on early impact and specific patient populations [51][52] Question: How does the company plan to use incremental free cash flow in the future? - The strategy includes reinvesting in R&D and potentially considering share buybacks or dividends if intrinsic value is not reflected in stock price [54][55] Question: Can you elaborate on launch readiness and expected regulatory catalysts? - The company plans to follow rigorous launch protocols similar to Attruby, with a focus on global launches and setting new standards of care [60][62] Question: What is the outlook on tafamidis IP and its impact on Attruby? - Management believes the tafamidis IP situation is a sideshow and does not impact Attruby's uptake, as the differentiated clinical data continues to drive momentum [78][83]

Core Viewpoint - Sharp Therapeutics Corp. is raising a minimum of US$10,000,000 through a non-brokered private placement, with shares priced at no less than US$2.50 each, expected to close in Q1 2026 [1] Group 1: Private Placement Details - The private placement will consist of common shares priced at not less than US$2.50 per share, with the offering expected to close in the first quarter of 2026 [1] - STX Partners, Sharp's largest shareholder, has committed to purchase at least 1,600,000 shares for approximately US$4,000,000, contingent upon the company raising at least US$6,000,000 from other investors [2] - The insider participation in the offering is classified as a related-party transaction, exempt from formal evaluation or minority shareholder approval under MI 61-101 [3] Group 2: Company Progress and Future Plans - Sharp is advancing its '901 candidate for Phase I trials in Gaucher disease, with STX's increased investment allowing the company to focus on generating key data supporting the treatment's effectiveness [4] - The company has made progress in its GBA1-Gaucher program, with pre-IND studies indicating that the '901 compound is well tolerated at higher doses, suggesting potential as a front-line therapy [5] - Sharp plans to file for Orphan Drug Designation for '901 with the US FDA in Q1 2026 [5] Group 3: Stock Options - The company granted 200,000 stock options to certain directors at an exercise price of CAD$1.48/US$1.07, with a 3-year vesting provision [6] - An additional 225,000 options were granted to an officer at an exercise price of CAD$2.21/US$1.60, also subject to a 3-year vesting provision [7] Group 4: Company Overview - Sharp Therapeutics is a preclinical-stage company focused on developing small-molecule therapeutics for genetic diseases, utilizing a discovery platform that combines high throughput screening technologies [8]

Core Viewpoint - Kamada Ltd. has decided to discontinue its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD) due to low likelihood of demonstrating a statistically significant benefit in lung function [1][3]. Company Updates - The discontinuation of the trial follows advice from an independent Data and Safety Monitoring Board (DSMB) based on a prespecified interim futility analysis [3]. - CEO Amir London expressed disappointment over the trial's outcome but emphasized the company's strong position for future growth prospects [4]. - Kamada reiterated its full-year 2025 revenue guidance of $178 million to $182 million, aligning closely with the consensus of $180.66 million, and provided adjusted EBITDA guidance of $40 million to $44 million [5]. Future Outlook - The company projects double-digit growth in revenues and profitability for 2026, supported by its commercial portfolio, which includes six FDA-approved specialty plasma-derived products marketed in over 30 countries [6]. - Kamada is also focusing on expanding its biosimilar portfolio in Israel and increasing plasma collection capacity, while pursuing new business development opportunities to ensure long-term growth [6]. Market Reaction - Following the announcement, Kamada's stock experienced a decline of 5.51%, trading at $6.69 [7].

Core Insights - The FORTIFY Phase 3 study of BBP-418 has successfully achieved all primary and secondary interim analysis endpoints with a well-tolerated safety profile consistent with prior studies [1] - BBP-418 treatment resulted in a significant increase in glycosylated αDG by 1.8 times from baseline at 3 months, with sustained improvements at 12 months [1][4] - The average reduction in serum CK, a marker of muscle damage, was 82% from baseline at 12 months in BBP-418 treated individuals, showing a statistically significant difference versus placebo [1][4] - The company plans to file a New Drug Application (NDA) with the FDA in the first half of 2026 [1][5] Study Results - The FORTIFY study is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating BBP-418 for LGMD2I/R9 [3] - Key results at 12 months include: - Ambulatory function (100MTT): Increase in velocity of 0.14 m/s from baseline and 0.27 m/s versus placebo (p<0.0001) [3][4] - Pulmonary function (FVC): Increase of approximately 3% predicted volume from baseline and a difference of about 5% versus placebo (p=0.0071) [3][10] Safety and Regulatory Designations - BBP-418 was well-tolerated with no new or unexpected safety findings observed [10] - The drug has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA, as well as Orphan Drug Designation from the EMA [6] Disease Background - LGMD2I/R9 is a monogenic autosomal recessive disease caused by mutations in the FKRP gene, leading to impaired glycosylation of αDG [7] - Clinical manifestations include skeletal myopathy, pulmonary muscle involvement, and cardiac issues, with significant morbidity in affected individuals [7] Company Overview - BridgeBio Pharma, Inc. is focused on discovering and delivering transformative medicines for genetic diseases, with a commitment to applying advances in genetic medicine [8]